Cover Image

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy

Saved in:

Bibliographic Details
Main Authors:	Minhye Kim (Author), Ji Min Na (Author), Gyeong-Won Lee (Author), Seung Jun Lee (Author), Jong Duk Kim (Author), Jung Wook Yang (Author)
Format:	Book
Published:	Korean Society of Pathologists & the Korean Society for Cytopathology, 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020)

EGFR Mutation in Nasopharyngeal Carcinoma
by: Evren Uzun, et al.
Published: (2022)

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
by: Xiaohong Liu, et al.
Published: (2024)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021)

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
by: Michael Menzel, et al.
Published: (2024)

Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC
by: Long Mao, et al.
Published: (2020)

Absence of PIK3CA mutation in primary mucinous ovarian carcinoma: An analysis of 20 Taiwanese cases by FemtoPath PIK3CA mutation screen kit
by: Wan-Ru Chao, et al.
Published: (2022)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
by: Ki-Chang Lee, et al.
Published: (2021)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

Discordant EGFR mutation results: A case report
by: Ullas Batra, et al.
Published: (2022)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR<sup>L858R/T790M</sup> Mutations
by: Moamen A. Hassanin, et al.
Published: (2022)

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024)

Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
by: Yang Chen, et al.
Published: (2023)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019)

Study of EGFR mutations in head and neck squamous cell carcinomas
by: Gurpreet Kaur, et al.
Published: (2021)

The urine as a diagnostic key for a homozygous EGFR mutation
by: Mafalda Casinhas Santos, et al.
Published: (2022)

Mutations of the PIK3CA gene in patients with breast cancer in the Krasnoyarsk region
by: A. V. Zyuzyukina, et al.
Published: (2024)

Deep learning‐based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images
by: Jun Hyeong Park, et al.
Published: (2024)

Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
by: Luigi Della Gravara, et al.
Published: (2023)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
by: Jun Fan, et al.
Published: (2020)

Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report
by: Tillmann Bedau, et al.
Published: (2024)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012)

Worldwide variations in <it>EGFR </it>somatic mutations: a challenge for personalized medicine
by: Lamy Pierre-Jean, et al.
Published: (2012)

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
by: Jeonghyo Lee, et al.
Published: (2022)

Muscle hemihypertrophy syndrome with PIK3CA gene mutation associated with Tourette syndrome
by: Mathilde Hayoun-Vigouroux, MD, et al.
Published: (2022)

Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus
by: Ludmilla Queirós Miranda, et al.
Published: (2013)

The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
by: Haitao Wang, et al.
Published: (2024)

CLOVES syndrome caused by mosaic mutation in the PIK3CA gene identified in fibroblasts
by: Magdalena Kłaniewska, et al.
Published: (2021)

Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population
by: Qingfeng Huang, et al.
Published: (2022)

Pulmonary Vein Stenosis Associated with Germline <i>PIK3CA</i> Mutation
by: Delphine Yung, et al.
Published: (2022)

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits
by: Eszter Bencze, et al.
Published: (2022)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
by: Yun Zhang, et al.
Published: (2021)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
by: M. Yoon, et al.
Published: (2016)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
by: Federica Pecci, et al.
Published: (2022)

Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery
by: Olga Furman, et al.
Published: (2022)

Synchronous Recto-Sigmoid Colorectal Carcinomas With Microsatellite Instability and an Activating PIK3CA Mutation
by: Mohit Mathavan MD, et al.
Published: (2022)

Differential MicroRNA Expression between T790M and L858R Mutated Lung Cancer
by: Ji Yeon Kim, et al.
Published: (2018)